CERo Therapeutics’ (CERO) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of CERo Therapeutics (NASDAQ:CERO) in a report issued on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $30.00 target price on the stock.

Separately, D Boral Capital raised CERo Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, June 23rd. One equities research analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company. According to MarketBeat.com, CERo Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $45.00.

CERo Therapeutics Price Performance

Shares of NASDAQ:CERO opened at $5.38 on Tuesday. CERo Therapeutics has a 12 month low of $4.27 and a 12 month high of $895.40. The company’s 50-day moving average price is $7.13 and its two-hundred day moving average price is $10.99.

CERo Therapeutics (NASDAQ:CERO) last released its earnings results on Friday, August 22nd. The company reported ($61.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($70.23) by $8.52.

Institutional Investors Weigh In On CERo Therapeutics

An institutional investor recently bought a new position in CERo Therapeutics stock. Parallel Advisors LLC bought a new position in CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 220,000 shares of the company’s stock, valued at approximately $161,000. Parallel Advisors LLC owned 7.26% of CERo Therapeutics as of its most recent filing with the Securities & Exchange Commission. 29.64% of the stock is owned by institutional investors and hedge funds.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.